The Effect of Education and Tele-Follow-Up Program on Diabetes Self-Management and Blood Glucose Regulation
Condition(s) studied
Investigational drug(s) / intervention(s)
Diabetic DM: The intervention group will receive 45 minutes of diabetes education. Three telemonitoring sessions will be held 2 weeks, 1 month and 3 months after the education. During the monitoring, participants will be asked to monitor their blood sugar and HbA1C values, if any. Nothing will be done to the control group. The same monitoring will be held for the control group 3 months later.
Study summary
This study is designed as a randomized controlled trial to determine the effects of education and the Tele-Follow-up program on the disease knowledge, self-management, and blood glucose regulation of newly diagnosed Type 2 diabetes patients.
Eligibility
Primary outcome measure(s)
- Diabetes Self-Management Scale — Baseline and after 6 months
As a result of the study by Koç and his colleagues, a new measurement tool called "Type 2 Diabetes Self-Management Scale" was developed. A minimum of 19 and a maximum of 95 points can be obtained from the scale. There is no cut-off score range for the scale. According to the total score average, high scores indicate good self-management, while low scores indicate poor self-management. - Adult Diabetes Knowledge Scale — Baseline and after 6 months
The scale was developed by Erener Yavuz and Erol (2019) to measure the knowledge levels of adult diabetic individuals. The maximum score that can be obtained from the scale is 28, and the minimum score is 0. Scores between 14 and 28 indicate a high level of knowledge, while scores below 14 indicate insufficient level of knowledge.
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Çanakkale Onsekiz Mart University, Faculty of Health Sciences | Çanakkale | Turkey (Türkiye) | |
| Çanakkale Onsekiz Mart University, Faculty of Health Sciences | Çanakkale | Çanakkale |
More Çanakkale Onsekiz Mart University trials in Turkey
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06963073 on ClinicalTrials.gov ↗ ← All trials in Turkey